What is Johnson & Johnson's CAPLYTA — sales to customers (note 9)?

Johnson & Johnson (JNJ) reported CAPLYTA — sales to customers (note 9) of $270M in Q1 2026.

What does CAPLYTA — sales to customers (note 9) mean?

This metric represents the total net revenue generated from the sale of the specific pharmaceutical product line to external customers. It serves as a primary indicator of the product's market adoption, commercial success, and contribution to the company's overall top-line performance. Tracking this figure allows investors to assess the revenue trajectory and demand stability of this specific therapeutic asset within the broader portfolio.

Johnson & Johnson JNJ CAPLYTA — Sales to customers (Note 9)

Other product segments

ELECTROPHYSIOLOGY

$5.63B+7.0%

DARZALEX

$3.96B+22.5%

Other

$2.9B+2.1%

SPINE,SPORTS & OTHER

$2.85B-2.5%

Tremfya

$1.61B+68.2%

GENERAL

$1.39B+4.9%

ADVANCED

$1.12B+4.7%

INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA

$1.04B+15.0%

CONTACT LENSES / OTHER

$969M+5.4%

ERLEADA

$949M+23.1%

TRAUMA

$833M+7.9%

SPINE & OTHER

$694M+3.4%

IMBRUVICA

$660M-6.9%

STELARA

$656M-59.6%

SIMPONI / SIMPONI ARIA

$647M-1.8%

XARELTO

$642M-7.0%

OPSUMIT/OPSYNVI

$606M+16.1%

CARVYKTI

$597M+61.8%

UPTRAVI

$483M+7.1%

SPRAVATO

$468M+46.3%

PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA

$443M+9.9%

HIPS

$436M+6.6%

Remicade

$422M-9.6%

KNEES

$420M+8.0%

EDURANT/rilpivirine

$409M+14.2%

other cardiovascular

$397M+4.5%

SURGICAL

$396M+9.7%

OTHER NEUROSCIENCE

$262M-5.4%

RYBREVANT + LAZCLUZE

$257M+82.3%

Tecvayli

$202M+33.8%

Other Oncology

$192M-10.3%

TALVEY

$152M+76.7%

CONCERTA/Methylphenidate

$136M-8.1%

OTHER IMMUNOLOGY

$46M+4,500%

OTHER INFECTIOUS DISEASES

$37M-9.8%

Similar metrics at other companies

LNTHPYLARIFY — Revenue

$240.92M-6.5%

MIRMProduct sales, net — Product sales, net

$159.88M+43.3%

PFEInlyta — Revenues:

$214M-2.3%

CRMDProduct sales, net — Total Revenue

$121.92M+212%

ARDXProduct sales, net — Total revenues

$93.37M+37.7%

LGNDCapvaxive — Total revenues and income

$1.97M+122%

Other financials

Income statement

See full

Revenue$24.1B+9.9%

Gross profit$16.0B+9.8%

Operating income$6.3B+2.3%

Net income$5.2B-52.4%

EPS (diluted)$2.14-52.9%

Balance sheet

See full

Cash & equivalents$21.7B-43.6%

Total debt$55.0B+5.2%

Total equity$81.2B+3.9%

Total assets$200.89B+3.7%

Cash flow

See full

Operating cash flow$2.5B-39.8%

CapEx$1.0B+31.9%

Free cash flow$1.5B-56.6%

Valuation

See full

Market cap$623.71B+66.9%

Enterprise value$657.01B+61.9%

P/E29.6×+13.2×

P/S6.5×+2.3×

Profitability

See full

Gross margin67.8%-0.5pp

Operating margin26.4%+2.8pp

Net margin21.8%-2.6pp

FCF margin18.5%-4.3pp

Returns & leverage

See full

Return on equity26.4%-3.0pp

Debt / equity0.7×0.0×

Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's caplyta — sales to customers (note 9).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Johnson & Johnson's CAPLYTA — sales to customers (note 9)?: Johnson & Johnson (JNJ) reported CAPLYTA — sales to customers (note 9) of $270M in Q1 2026.
What does CAPLYTA — sales to customers (note 9) mean?: This metric represents the total net revenue generated from the sale of the specific pharmaceutical product line to external customers. It serves as a primary indicator of the product's market adoption, commercial success, and contribution to the company's overall top-line performance. Tracking this figure allows investors to assess the revenue trajectory and demand stability of this specific therapeutic asset within the broader portfolio.